EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

EDSA：EB01第二階段試驗的登記工作將於22…第四季度完成

Benzinga Real-time News · 2022/05/24 22:45

By David Bautz, PhD

作者：David Bautz博士

NASDAQ:EDSA

納斯達克：法國電力公司

READ THE FULL EDSA RESEARCH REPORT

閲讀完整的EDSA研究報告

Business Update

商業動態

Enrollment for Phase 2b Trial of EB01 Estimated to Complete in 4Q22

EB01第二階段試驗的登記工作預計將於22季度完成

Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total suffering from chronic allergic contact dermatitis (ACD) (NCT03680131). The company is also conducting an exploratory, dose-ranging component of the study, which will separately evaluate lower-strength concentrations of EB01 in 40 additional subjects.

愛德莎生物技術公司(納斯達克代碼：EDSA)目前正在進行一項雙盲、安慰劑對照試驗，以評估2.0%EB01乳膏在大約170名患有慢性過敏性接觸性皮炎(ACD)的可評估受試者中的安全性和有效性(NCT03680131)。該公司還在進行這項研究的探索性、劑量範圍的組成部分，該研究將在另外40名受試者中單獨評估較低強度的EB01濃度。

In June 2021, Edesa announced positive interim results for EB01 in the Phase 2b trial. The initial study cohort consisted of...

2021年6月，EDESA宣佈了EB...

登入免費觀看全文

登入/註冊

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

風險及免責聲明

聲明